蛋白质基因组特征识别EGFR和ALK的临床亚组,野生型从不吸烟的肺腺癌
Hyondeog Kim1, Wonyeop Lee2, Youngwook Kim3,4
1Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Gyeonggi-do, Republic of Korea.
Experimental & molecular medicine
|September 19, 2024
概括
这项研究揭示了在没有EGFR/ALK突变的从未吸烟者肺腺癌中四种蛋白质基因组亚型. 免疫亚型显示出最好的预后,而增殖和血管新生亚型显示出较差的结果,指导未来的肺癌疗法.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 蛋白质组学是指蛋白质组学.
背景情况:
- 没有EGFR/ALK突变的不吸烟肺腺癌 (NSLA) 患者的向治疗选择有限,对免疫检查点抑制剂的反应较差.
- 这些NSLA瘤的蛋白质基因组景观尚不清楚,因此临床上需要精确的分子分类.
研究的目的:
- 综合分析没有EGFR或ALK驱动突变的NSLA瘤的基因组,转录组和蛋白质组.
- 将这些瘤分为蛋白质基因组子组,并将它们与临床结果联系起来.
- 在这些子组中识别潜在的治疗点.
主要方法:
- 来自99名韩国从未吸烟的肺腺癌患者的基因组,转录组和LCMS/MS-TMT蛋白质组数据的分析.
- 蛋白质基因组分为四个子组:增殖,血管生成,免疫和新陈代谢.
- 用转录组和蛋白质组数据对基因组变化的相关性分析.
- 在外部肺癌数据集中验证子组结果关联.
主要成果:
- 在缺乏EGFR/ALK突变的NSLA瘤中确定了四个不同的蛋白质基因组子组 (增殖,血管生成,免疫,新陈代谢).
- 免疫子组与最有利的预后有关,而增殖和血管新生亚型与较差的结果相关.
- 在拷贝数变化和基因表达/蛋白质水平之间观察到显著的相关性,丰富ERBB,神经,胰岛素和MAPK信号通路.
- 确定了潜在的治疗点,包括CDK和ATR在增殖亚组,以及免疫亚组中的CCL5/CXCL13.
结论:
- 蛋白质基因组分析揭示了EGFR/ALK野生类型NSLA中不同的分子亚型,解决了重要的未满足的临床需求.
- 确定的子组与临床结果有很强的关联,提供预后价值.
- 该研究强调了针对特定NSLA分子亚型的潜在新型治疗策略,包括向药物和组合免疫疗法.
更多相关视频
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
7.9K
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
1.0K
相关概念视频
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
